Welcome to our dedicated page for Vivos news (Ticker: RDGL), a resource for investors and traders seeking the latest updates and insights on Vivos stock.
Vivos Inc. develops isotope-based radiotherapeutic products for targeted cancer treatment and related therapeutic applications. News about RDGL centers on RadioGel® for human use, IsoPet® for veterinary applications, and the company’s Precision Radionuclide Therapy™ approach, which is designed to deliver localized beta radiation directly to tumor sites while limiting exposure to surrounding tissue.
Recurring developments include FDA IDE-related work for RadioGel®, international human therapy demonstrations, veterinary clinic certification and IsoPet adoption, intellectual-property protection for hydrogel and radiotherapy technology, manufacturing arrangements for yttrium-90 phosphate particles and sterile hydrogel doses, and strategic collaborations in companion-animal radiotherapeutics.
Vivos Inc (RDGL) has announced its participation in the LD 500 investor conference, scheduled for September 3, 2020, at 1:40 PM PST. Dr. Mike Korenko, CEO, will present virtually, emphasizing the accessibility of this event amid COVID-19 restrictions. The conference runs from September 1 to 4, offering a platform for unique companies in the microcap space. Vivos specializes in an Yttrium-90 based injectable brachytherapy device for treating tumors in humans and animals, utilizing proprietary hydrogel technology for targeted radiation treatment.